Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amdiglurax - Alto Neuroscience

Next Previous
Drug Profile

Amdiglurax - Alto Neuroscience

Alternative Names: ALTO-100; NSI-189; NSI-189 - Neuralstem; NSI-189 phosphate

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuralstem
  • Developer Alto Neuroscience; Palisade Bio; University of California, San Diego
  • Class Antidepressants; Antihyperglycaemics; Anxiolytics; Neuroprotectants; Nootropics; Piperazines; Pyridines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Brain derived neurotrophic factor modulators; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar depression
  • Discontinued Alzheimer's disease; Angelman syndrome; Brain injuries; Cognition disorders; Diabetic neuropathies; Ischaemic stroke; Major depressive disorder; Neurodegenerative disorders; Post-traumatic stress disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 27 May 2026 Discontinued - Phase-II for Major depressive disorder in USA (PO) (Alto Neuroscience Pipeline, May 2026)
  • 27 May 2026 Discontinued - Phase-II for Post-traumatic stress disorders in USA (PO) (Alto Neuroscience Pipeline, May 2026)
  • 27 May 2026 Discontinued - Preclinical for Alzheimer's disease in USA (PO) (Alto Neuroscience Pipeline, May 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top